Trial Talk

In the first episode of our new Trial Talk series, Hanif Esmail and Conor Tweed take over the microphones to interview Andrew Nunn and Sarah Meredith, who have both recently retired from the Unit, having spent a combined total of 92 years working in the field of tuberculosis (TB). As we celebrate Andrew and Sarah’s long and accomplished careers, we’ll dive into the history of TB clinical trials and muse on the future of TB research.

For more information and to access the transcript: https://www.mrcctu.ucl.ac.uk/news/news-stories/2024/january/new-podcast-episode-careers-in-tb-clinical-trials

Check out our earlier podcast episodes about TB trials, also featuring Andrew Nunn:
• Trial-talk-podcast – The-stream2-trial-how-should-we-treat-multi-drug-resistant-tuberculosis
• Trial-talk-podcast – Andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-1
• Trial-talk-podcast – Andrew-nunn-talks-medical-statistics-tb-and-algerian-nomads-part-2

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

 Date of episode recording: 2024-01-26T00:00:00Z
 Duration: 28:56
 Language of episode: English 
 Presenters: Charlotte Hartley, Hanif Esmail, Conor Tweed
 Guests: Andrew Nunn, Sarah Meredith
 Producer: Charlotte Hartley
 
The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this new series, we will hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections, and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.

What is Trial Talk?

The Trial Talk Podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this new series, we will hear from world-leading experts about the studies we carry out. We will get inside trials on cancer, infections, and neurodegenerative diseases, explore how public and patient involvement is shaping our studies, and discover new ways to run smarter studies.